Home
    Disclaimer
    ← Back to mCPP
    mCPP molecular structure

    mCPP Stats & Data

    Stimulant Research-chemical
    Cpp 3-cpp Meta-chlorophenylpiperazine
    PubChem CID 7153
    NPS DataHub
    MW196.68
    FormulaC10H13ClN2
    CAS6640-24-0
    IUPAC1-(3-Chlorophenyl) piperazine
    SMILESClc1cccc(c1)N1CCNCC1
    InChIKeyVHFVKMTVMIZMIK-UHFFFAOYSA-N
    Piperazines
    Psychoactive Class Stimulant

    Pharmacology

    DrugBank

    Description

    m-Chlorophenylpiperazine has been used in trials studying the treatment of Alcoholism.

    Receptor Profile

    Receptor Actions

    Agonists
    5-HT2B receptor partial agonist
    5-HT2C receptor partial agonist
    Antagonists
    5-HT2A receptor antagonist
    Inhibitors
    Serotonin reuptake inhibitor
    Other
    Serotonin releasing agent

    Receptor Binding

    serotonin reuptake inhibitor

    Toxicity

    PsychonautWiki PubChem

    It is strongly recommended that one use harm reduction practices when using this drug.

    Carcinogenicity

    2B, possibly carcinogenic to humans. (L135)

    Effect Profile

    Curated + 7 Reports
    Stimulant 4.1

    Strong anxiety/jitters with moderate stimulation, mild euphoria

    Stimulation / Energy×3
    7
    Euphoria / Mood Lift×2
    5
    Focus / Productivity×2
    0
    Anxiety / Jitters×1
    8
    Based on reports from:
    Erowid Experience Reports PsychonautWiki mCPP

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1d Half tolerance 10d Baseline ~18d

    Experience Report Analysis

    Erowid
    7 Reports
    2005–2009 Date Range
    1 With Age Data
    10 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 7 experience reports (7 Erowid)

    7 Reports
    10 Effects Detected
    4 Positive
    5 Adverse
    1 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 4

    Euphoria 100.0% 70%
    Color Enhancement 57.1% 70%
    Tactile Enhancement 57.1% 70%
    Stimulation 42.9% 70%

    Adverse Effects 5

    Anxiety 85.7% 70%
    Nausea 85.7% 70%
    Jaw Clenching 57.1% 70%
    Pupil Dilation 57.1% 70%
    Headache 42.9% 70%

    Real-World Dose Distribution

    62K Doses

    From 1 individual dose entries

    Form / Preparation

    Most common forms and preparations reported

    Read full reports on Erowid →

    Legal Status

    Country Status Notes
    Austria Since January 1, 2012, mCPP is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).
    Belgium mCPP is a controlled substance as of October 22, 2006.
    Brazil mCPP is a controlled substance ( lista F2 da Portaria SVS/MS 344/98 ) since November 2008.
    China As of October 2015, mCPP is a controlled substance in China.
    Denmark mCPP is a controlled substance as of December 3, 2005.
    Finland mCPP is a controlled substance.
    Germany mCPP is controlled under Anlage II BtMG ( Narcotics Act, Schedule II ) as of March 1, 2007. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
    Greece mCPP is a controlled substance as of January 20, 2005.
    Hungary mCPP is a controlled substance as of January 1, 2006.
    Japan mCPP is a controlled substance since 2006.
    Lithuania mCPP is a controlled substance as of July 1, 2006.
    Norway mCPP is a controlled substance.
    Poland mCPP is a controlled substance.
    Russia mCPP is a controlled substance.
    Sweden mCPP is a controlled substance.
    Switzerland mCPP is a controlled substance specifically named under Verzeichnis D.
    United Kingdom mCPP is a Class C, Schedule 4 (Part 1) drug in the United Kingdom.
    United States mCPP is unscheduled in the United States, but could be considered an analogue of benzylpiperazine if it is sold for human consumption.

    References

    Data Sources

    Cited References

    ← Back to mCPP